VIDEO: Sight Sciences shares updates on GEMINI, SAHARA trials
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Matt Link, chief commercial officer of Sight Sciences, shares information on the company’s clinical trials.
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Matt Link, chief commercial officer of Sight Sciences, shares information on the company’s clinical trials.
ATLANTA — Obicetrapib, a novel cholesteryl ester transfer protein inhibitor, reduced atherogenic lipoprotein particles alone or in combination with ezetimibe, according to new data from…
Researchers found the model demonstrated “near-perfect” detection capabilities.
David Hutton, Managing Editor of Ophthalmology Times sat down with Claris Bio CEO, Clarke Atwell, to discuss the company’s path toward developing treatment for neurotrophic…
In older men, the sleep breathing impairment index definition of combined insomnia-obstructive sleep apnea predicted incident diabetes, according to results published in Annals of the…
Unveiling the Power List – a comprehensive ranking of the top 100 most influential ophthalmologists worldwide. Browse the list to find leading eye care experts,…
Patients with obstructive sleep apnea and obesity hypoventilation syndrome each had elevated odds for extended nonsurgical hospital stays and high costs, according to results published…
The Biden-Harris Administration released the 2024 National Strategy for Suicide Prevention and Federal Action Plan, which includes actions to address substance use and suicide risk…
Ocular surface disease must be addressed before cataract surgery to ensure patient satisfaction and good surgical outcomes, according to a presentation at Real World Ophthalmology.
What can we learn about the safety, efficacy, and biosimilarity of BYOOVIZ (Biogen) from a phase 3 sstudy? Anat Loewenstein, MD, explains to David Brown,…
The FDA has approved an updated label for Lupkynis, an oral treatment for active lupus nephritis, that includes long-term safety and tolerability data, and eases…